In-depth analysis of research on myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Formerly known as ME/CFS Skeptic.
https://mecfsscience.org/
ME/CFS Science
Loading...
7) This was a presentation at the end of May 2026, at the 15th International Biomedical Research into ME Colloquium (BRMEC15).
The full video is available on the Invest in ME website:
6) in ME/CFS they recommend starting with low dose studies. This reduces costs but also side effect and adverse events which can set back trial development for many years. ME/CFS patients are particularly sensitive to medication changes and side effects.
5) Precisionlife has been using its AI-driven combinatorial analytics platform to find genetic drivers of GLP-1 efficacy so that they can predict and stratify strong and weak responders.
More info:
4) Because of the heterogeneity in ME/CFS, different drugs will work for different people - no single trial will benefit everyone. For GLP-1 RA, they recommend focusing on three subgroups: autoimmune/inflammatory, cardiovascular and/or energy metabolism.
3) In a previous analysis they also looked at genes that are protective for ME/CFS and several were involved in type-2 diabetes, insulin-related signalling, BMI, etc. That's another reason why they are interested in the GLP-1 drugs.
Link:
2) They have an interest in GLP-1 RA because it affects biological pathways that come up in the ME/CFS genes they identified such as synaptic and calcium signalling, glucose homeostatis and endothelial dysfunction.
1) Watched this presentation by Dr. Steve Gardner from PrecisionLife.
Their genetic analysis suggests that ME/CFS is highly polygenic and heterogeneous. They are using their data to make drug repurposing trials more effective, for example on GLP-1 receptor agonists.
